Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Medical Cannabis can reduce or eliminate the use of opioids

<< Previous

Bullboard Posts

Next >>

Comment by SamV21on Mar 22, 2022 4:38pm

70 Views

Post# 34535764

RE:Medical Cannabis can reduce or eliminate the use of opioids

To bad the CEO from Tetra has constantly lied to shareholders about market and product deadlines and is years and 100s of millions of dollars away from having any saleable product .You can be sure big Pharma with deep pockets and EXPERIENCE IN BRINGING PRODUCT TO MARKET will come up with something that does not cause lung cancer or lung side effects and has no THC.
Qixleef will never be used in a hospital setting where there is oxygen and that is where most of the extreme pain is.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario